Every Hayes clinical evidence report is developed by experienced teams that have been trusted by healthcare decision makers since 1989. Here is a sampling of our content that is being used every day to inform defensible, evidence-based decisions by payers and providers.
Not all reports are available for public preview. For more information, please contact us.
The Flowsense device is a wireless, noninvasive thermal flow sensor in development for the detection of flow in implanted cerebrospinal fluid shunts in patients with hydrocephalus.
This report evaluates the clinical utility of whole genome sequencing (WGS) and whole exome sequencing (WES) in patients with a primary phenotype of intellectual disability (ID). In general, ID may be associated with other neurological disorders, various genetic syndromes, and autism spectrum disorders. However, this report focuses on patients whose primary phenotype of conce…
Teplizumab is an intravenously administered anti-CD3 monoclonal antibody in development for the delay or prevention of clinical type 1 diabetes (T1D) in at-risk individuals.
Focus of the Report: This report focuses on the use of transcatheter mitral valve replacement (TMVR) for treating mitral regurgitation (MR), backward flow of blood due to a damaged or leaking mitral valve (MV) in the heart.
Technology Description: TMVR is a treatment for MR that uses percutaneous access through a peripheral artery to place a bioprosthe…
Focus of the Report: This report focuses on intradialytic parenteral nutrition (IDPN) for nutritional support in adults with end-stage renal disease (ESRD) who are undergoing hemodialysis.
Technology Description: IDPN is an intravenous infusion of essential nutrients administered durin…
Inolimomab (proposed name, Leukotac) is an immunotherapy monoclonal antibody targeting the interleukin-2 receptor (IL-2) in development for the treatment of acute graft versus host disease (aGVHD).
Focus of the Report: The use of radiofrequency ablation (RFA) of the genicular nerves for the treatment of osteoarthritis of the knee (KOA).
Technology Description: In this report, RFA is defined as ablation of the peripheral nerves of the knee to relieve the pain associated with KOA. The …
Inclisiran is a subcutaneously administered, investigational RNAi therapeutic that decreases hepatic synthesis of proprotein convertase subtilisin kexin type 9 (PCSK9), leading to increased low-density lipoprotein (LDL) receptor expression on the hepatocyte cell surface and subsequently to greater removal of LDL-C from circulation.
Focus of the Report: This report focuses on the efficacy and safety of the 5-hydroxytryptamine 1F (5-HT1F) receptor agonist lasmiditan (Reyvow) for acute treatment of migraines.
Technology Description: The 5-HT1F receptors are…
The report evaluates the analytical validity, clinical validity, and clinical utility of the VeriStrat test, a liquid biopsy-based proteomic test that identifies a chronic inflammatory immune response indicative of aggressive disease in patients with advanced non-small cell lung cancer (NSCLC) and is intended to provide prognostic information to assist physicians with patient…